Kleine-Borgmann J, et al. - Researchers performed this trial to determine the effect of 3-week open-label placebo treatment on pain intensity and subjective and objective functional disability in patients with chronic back pain (CBP). Following a pretest–posttest design, they recruited 127 patients with CBP (pain duration > 12 weeks) from the Back Pain Center, Neurology, University Hospital Essen, Germany. Patients in the open-label placebo group were provided a 3-week open-label placebo treatment. No intervention was provided to patients in the treatment as usual (TAU) group. TAU was continued in both groups. Of 122 patients with CBP, 63 comprised open-label placebo group or 59 comprised TAU group. Outcomes support the 3-week open-label placebo treatment as safe. The patients with CBP well-tolerated this treatment and showed a reduction in pain, disability, and depressive symptoms.